Fate Therapeutics (FATE) Cash & Equivalents (2012 - 2026)

Fate Therapeutics (FATE) has 15 years of Cash & Equivalents data on file, last reported at $39.6 million in Q1 2026.

• Quarterly Cash & Equivalents fell 11.91% year-over-year to $39.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.6 million (down 11.91% YoY) and the FY2025 annual result came in at $46.6 million, up 29.32% from the prior year.
• Cash & Equivalents retreated to $39.6 million in Q1 2026, from $46.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $121.3 million in Q1 2024 to a low of $33.3 million in Q3 2023.
• A 5-year average of $51.3 million and a median of $42.0 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 188.72% — and 2025, when it slumped 62.97%.
• Tracing FATE's Cash & Equivalents over 5 years: stood at $61.3 million in 2022, then slumped by 31.73% to $41.9 million in 2023, then decreased by 13.89% to $36.1 million in 2024, then gained by 29.32% to $46.6 million in 2025, then fell by 15.14% to $39.6 million in 2026.
• The last three Cash & Equivalents figures came in at $39.6 million (Q1 2026), $46.6 million (Q4 2025), and $40.6 million (Q3 2025), per Business Quant data.